“We respect Parth Joshi’s decision to start his entrepreneurial journey,” a BharatPe spokesperson confirmed. At BharatPe, we ...

BharatPe CMO Parth Joshi has resigned and is serving his notice period to launch his own venture. The company confirmed his ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Vortex Biotech Holdings, (‘Vortex’, or ‘the Company’), a leading oncology liquid biopsy company, is pleased to announce the appointment of Nigel Brooksby as Non-Executive Chairman. Nigel is an ...

This breadth of mutational coverage, in addition to high selectivity which could improve tolerability, provides potential for a best-in-class profile. Luke Miels, Chief Commercial Officer ...

The EC has approved GSK's Jemperli (dostarlimab) combined with chemotherapy for primary advanced or recurrent endometrial ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.

The Boston company emerged in 2022 with $ ... demonstrate a manageable safety profile and favorable durability, according to GSK. Across 87 evaluable patients of all KIT mutation subsets, the ...

In 2023, GSK reported that Arexvy generated (PDF) sales of 1.238 million pounds sterling ($1.5 billion). In October, however, the company said that third-quarter sales of the shot had declined by ...

These data show promising anti-tumour activity of IDRX-42 in patients with advanced GIST with a manageable safety profile. Across patients ... and prolong response to therapy. GSK is a global ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in ...